To hear about similar clinical trials, please enter your email below
Trial Title:
TME Alteration in HER2 Positive Breast Cancer
NCT ID:
NCT06533670
Condition:
Breast Cancer
HER2-positive Breast Cancer
Chemotherapy Effect
Conditions: Official terms:
Breast Neoplasms
Study type:
Observational [Patient Registry]
Overall status:
Recruiting
Study design:
Time perspective:
Prospective
Summary:
Evaluate for changes in the tumor microenvironment before/during neoadjuvant chemotherapy
and after treatment in patients diagnosed with HER2-positive advanced breast cancer and
receiving neoadjuvant cancer therapy and surgery for curative purposes.
Criteria for eligibility:
Study pop:
HER2 positive breast cancer patients undergoing curative treatment including neoadjuvant
chemotherapy after confirmation of breast cancer without distant metastases
Sampling method:
Non-Probability Sample
Criteria:
Inclusion criteria i. Adult patients over 18 years of age ii. Patients undergoing
curative treatment including neoadjuvant chemotherapy after confirmation of breast cancer
without distant metastases iii. Clinical T stage II-IV patients iv. HER2 positive breast
cancer patients
Exclusion criteria If you have other comorbidities that, according to the researcher's
judgment, may affect the results of the study
Gender:
All
Minimum age:
18 Years
Maximum age:
N/A
Healthy volunteers:
No
Locations:
Facility:
Name:
Seoul National University Hospital
Address:
City:
Seoul
Country:
Korea, Republic of
Status:
Recruiting
Contact:
Last name:
Wonshik Han
Phone:
+82-2-2072-1958
Email:
hanw@snu.ac.kr
Contact backup:
Last name:
Eunhye Kang
Phone:
+82-2-2072-2817
Email:
rkd4327@naver.com
Investigator:
Last name:
Wonshik Han
Email:
Principal Investigator
Investigator:
Last name:
Eunhye Kang
Email:
Sub-Investigator
Start date:
July 19, 2024
Completion date:
July 19, 2026
Lead sponsor:
Agency:
Seoul National University Hospital
Agency class:
Other
Source:
Seoul National University Hospital
Record processing date:
ClinicalTrials.gov processed this data on November 12, 2024
Source: ClinicalTrials.gov page:
https://clinicaltrials.gov/ct2/show/NCT06533670
